HRAS-Like Suppressor (HRASLS) (Internal Region) antibody

Details for Product No. ABIN238669, Supplier: Log in to see
Antigen
  • A-C1
  • HRASLS
  • H-REV107
  • HRASLS1
  • HRSL1
  • HSD28
  • 2810012B06Rik
  • Hrasrs
  • HRAS-like suppressor
  • zgc:92715
  • Hrasls
  • HRASLS
  • zgc:92715
  • hrasls
Epitope
Internal Region
15
14
3
1
1
1
1
1
1
Reactivity
Human, Mouse (Murine), Rat (Rattus)
30
6
6
1
1
1
1
Host
Goat
29
2
1
Clonality
Polyclonal
Conjugate
Un-conjugated
2
2
2
2
2
2
Method Type
Peptide ELISA
Application
ELISA, Western Blotting (WB)
28
4
3
3
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Immunogen Peptide with sequence C-RYGEGVSEQANR, from the internal region of the protein sequence according to NP_065119.1.
Blocking Peptide Blocking peptide for this product available: ABIN369844
Purification Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Alternative Name HRASLS / H-REV107 (HRASLS Antibody Abstract)
Background Synonyms: HRASLS, HRAS-like suppressor, A-C1, H-REV107, HRASLS1, HSD28, H-REV107 protein-related protein
Gene ID 57110, 27281, 288025
NCBI Accession NP_065119
Application Notes ELISA: antibody detection limit dilution 1:2000.
Western blot: Preliminary experiments in Human Heart, Skeletal Muscle, and Testis lysates gave no specific signal but low background (at antibody concentration up to 1 µg/mL).
Restrictions For Research Use only
Format Liquid
Buffer Supplied at 0.5 mg/mL in Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Minimize freezing and thawing.
Storage -20 °C
Storage Comment Aliquot and store at -20 °C.
Background publications Yanatatsaneejit, Chalermchai, Kerekhanjanarong, Shotelersuk, Supiyaphun, Mutirangura, Sriuranpong: "Promoter hypermethylation of CCNA1, RARRES1, and HRASLS3 in nasopharyngeal carcinoma." in: Oral oncology, Vol. 44, Issue 4, pp. 400-6, 2008 (PubMed).

Did you look for something else?